Oncolytics Biotech Inc.

Kara L Norman

Patrick W K Lee

Methods for treating proliferative disorders, by administering reovirus to a ral-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts target cancer cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), other serotypes or strains of reovirus, and recombinant reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.

Growing community of inventors

Menlo Park, CA, United States of America

Kara L Norman